Therapeutic advances in acute myeloid leukemia

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Alan BurnettBob Löwenberg

Abstract

The choice of treatment approach and outcome in acute myeloid leukemia (AML) depends on the age of the patient. In younger patients, arbitrarily defined as being younger than 60 years, 70% to 80% enter complete disease remission with several anthracycline-based chemotherapy combinations. Consolidation with high-dose cytarabine or stem-cell transplantation in high-risk patients will restrict overall relapse to approximately 50%. A number of demographic features can predict the outcome of treatment including cytogenetics and an increasing list of molecular features (ie, FLT3, NPM1, MLL, WT1, CEBPalpha, EVI1). These are increasingly being used to direct postinduction therapy, but they are also molecular targets for a new generation of small molecule inhibitors that are in early development; however, randomized data have yet to emerge. In older patients who comprise the majority, which will increase with demographic change, the initial clinical decision to be made is whether the patient should receive an intensive or nonintensive approach. If the same anthracycline/cytarabine-based approach is deployed, the remission rate will be around 50%, but the risk of subsequent relapse is approximately 85% at 3 years. This difference from yo...Continue Reading

References

Sep 30, 1999·The New England Journal of Medicine·B LöwenbergA Burnett
Jul 19, 2002·Archives of Internal Medicine·Joseph MenzinRajiv Mallick
Oct 24, 2002·Blood·Sahar Barjesteh van Waalwijk van Doorn-KhosrovaniRuud Delwel
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Dec 14, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ute HegenbartRainer Storb
Feb 4, 2006·Blood·Frederick R AppelbaumStephen H Petersdorf
May 3, 2008·The New England Journal of Medicine·Richard F SchlenkUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group
Jun 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter PaschkaClara D Bloomfield
Aug 12, 2008·Seminars in Oncology·Verena Gaidzik, Konstanze Döhner
Oct 9, 2008·Current Opinion in Oncology·Krzysztof MrózekClara D Bloomfield
Dec 3, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas BüchnerWolfgang Hiddemann
Mar 18, 2009·British Journal of Haematology·Alan K BurnettUNKNOWN United Kingdom National Cancer Research Institute Haematological Oncology Study Group
Apr 7, 2009·British Journal of Haematology·Keith WheatleyUNKNOWN United Kingdom National Cancer Research Institute Haematological Oncology Clinical Studies Group and Acute Myeloid Leukaemia
Jul 31, 2009·Cancer·Alois GratwohlUNKNOWN European Group for Blood and Marrow Transplantation and the European Leukemia Net
Sep 25, 2009·The New England Journal of Medicine·Bob LöwenbergUNKNOWN Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group
Sep 25, 2009·The New England Journal of Medicine·Hugo F FernandezMartin S Tallman
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franco MandelliTheo de Witte
Oct 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arati V RaoBob Löwenberg
Nov 12, 2009·Blood·Lars BullingerDirk van den Boom

❮ Previous
Next ❯

Citations

Jan 4, 2012·Cancer Chemotherapy and Pharmacology·Mikkel Krogh-MadsenPer Hartvig Honoré
Apr 30, 2013·Apoptosis : an International Journal on Programmed Cell Death·C HinterleitnerG Fritz
Oct 19, 2011·Current Treatment Options in Oncology·Alan K Burnett, Robert K Hills
Oct 8, 2011·Current Hematologic Malignancy Reports·E J Feldman, Usama Gergis
Nov 8, 2012·International Journal of Hematology·Brian McLaughlinMichael Boyiadzis
Oct 12, 2013·Immunology Letters·M MianoC Dufour
Apr 9, 2013·Leukemia·A S MooreC M Zwaan
Jun 12, 2012·Nature Medicine·Alex KentsisA Thomas Look
Dec 3, 2011·Nucleosides, Nucleotides & Nucleic Acids·Paula X Fernández-CalottiMarçal Pastor-Anglada
Oct 17, 2013·Japanese Journal of Clinical Oncology·Tatsuya SuzukiMichinori Ogura
Jan 18, 2012·Current Opinion in Hematology·Alan K Burnett
Feb 6, 2013·Current Opinion in Hematology·Mathijs A Sanders, Peter J M Valk
Jul 5, 2013·Journal of Pediatric Hematology/oncology·Amy ShafeyLillian Sung
Aug 8, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Erin L SchenkScott H Kaufmann
Jul 1, 2011·Biological Chemistry·Nuno CerveiraManuel R Teixeira
Dec 14, 2011·Critical Reviews in Oncogenesis·Er-Chieh ChoKathleen M Sakamoto
Jun 14, 2014·Journal of Translational Medicine·Himalee SabnisKevin D Bunting
Aug 2, 2013·Future Oncology·Courtney D DiNardoFarhad Ravandi

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.